Which corticosteroid is considered safest for giant papillary conjunctivitis (GPC)?

• A. Pred Forte
• B. Rimexolone
• C. Lotemax
• D. Durezol

Answer: (C)

When managing giant papillary conjunctivitis, the goal is to control inflammation while minimizing steroid-related side effects, especially spikes in intraocular pressure and cataract risk from longer use.

Loteprednol etabonate is a “soft” corticosteroid designed to be active where needed but rapidly inactivated in ocular tissues. This means it provides anti-inflammatory effect with a lower likelihood of elevating intraocular pressure or causing other steroid-related adverse effects compared with more potent steroids. For chronic surface inflammation like GPC, this safety profile makes it the preferred choice.

Other options like prednisolone acetate and difluprednate are more potent and carry higher risks of IOP rise and longer-term complications, while rimexolone is milder but not as favorable as loteprednol in the safety context for ongoing management.